Loading organizations...

Lumere is a technology company.
Lumere provides data and analytics solutions, empowering healthcare organizations with evidence-based decision-making. Its core offering helps hospitals reduce unwarranted clinical variation, focusing on medical device and drug selection. Through analysis, Lumere optimizes procurement, improving patient care outcomes and operational efficiencies.
Co-founded in 2012 as Procured Health by CEO Hani Elias, the company emerged from a critical insight into healthcare procurement. Elias and his team observed hospitals lacked objective tools for evaluating medical devices and pharmaceuticals. This absence of data-driven intelligence often led to suboptimal purchasing and increased costs, which Lumere aimed to address.
Healthcare systems nationwide utilize Lumere's platform to enhance clinical effectiveness and operational efficiency. Lumere's vision is to transform healthcare by equipping providers with insights to deliver high-value care. Now part of GHX, the company advances clinically integrated supply chains, aligning financial decisions with clinical imperatives, benefiting patients and providers.
Lumere has raised $15.0M across 3 funding rounds.
Lumere has raised $15.0M in total across 3 funding rounds.
Lumere (formerly Procured Health) is a healthtech software company that provides evidence-based data, analytics, and insights to help healthcare systems reduce clinical variation, optimize supply chain decisions for medical devices and pharmaceuticals, and cut unnecessary costs.[1][2][3][4] It serves health systems, clinicians, hospital administrators, and suppliers by enabling clinically integrated supply chains, better medication formulary management, and alignment of purchasing with clinical evidence to support value-based care.[3][5] Acquired by Global Healthcare Exchange (GHX) in 2020, Lumere now operates as a GHX company, headquartered in Chicago, IL, with about 106 employees as of available records.[2][3][5]
The platform leverages advanced machine learning, clinical data, and industry-standard product categorization to address unwarranted variation in device and drug utilization, driving cost savings and improved patient outcomes.[1][3][4] Post-acquisition, it integrates with GHX's supply chain data to enhance collaboration across healthcare stakeholders.[3]
Founded in 2012 and initially known as Procured Health, Lumere emerged from a team of clinicians, researchers, pharmacists, and strategic thought leaders focused on tackling healthcare inefficiencies through data-driven insights.[2][5] Early investors included Bessemer Venture Partners (initial investment in 2012) and F-Prime Capital, supporting its growth in the healthtech and services sector.[1][2] The company gained traction by developing solutions for evidence-based supply chain decisions, particularly in device and drug selection.[1][3]
A pivotal moment came in 2020 when GHX acquired Lumere to combine its clinical analytics with GHX's supply chain platform, accelerating advancements in clinically integrated supply chains and pharmaceutical management.[3] This acquisition marked Lumere's evolution from standalone startup to a key component of a larger healthcare ecosystem, headquartered in Chicago.[2][5]
Lumere rides the trend toward value-based care and clinically integrated supply chains, where data analytics bridge clinical decisions and procurement to manage rising healthcare costs amid complex pharmaceutical markets.[3] Its timing aligns with post-2020 shifts emphasizing data interoperability and cost optimization, fueled by market forces like supply chain disruptions and the push for evidence-driven utilization over volume-based models.[1][3]
By influencing healthcare ecosystems through GHX's connected network, Lumere enables billions in savings, better patient care, and risk management, positioning it as a catalyst for industry-wide collaboration between suppliers, providers, and clinicians.[3] This contributes to broader healthtech momentum in AI-powered analytics for sustainable care delivery.[4][5]
Post-acquisition, Lumere's trajectory ties to GHX's expansion in pharmaceutical analytics and supply chain integration, with potential to scale AI-driven insights across more health systems amid ongoing value-based care adoption.[3] Emerging trends like advanced ML for real-time formulary optimization and deeper data interoperability will shape its growth, amplifying influence in cost containment and clinical outcomes.[3][4]
As a GHX pillar, Lumere remains poised to drive systemic change in healthcare delivery, evolving from cost-reduction insights to a foundational enabler of efficient, evidence-led ecosystems—fulfilling its founding ambition to transform medical care through unbiased data.[5]
Lumere has raised $15.0M in total across 3 funding rounds.
Lumere's investors include Jesse Bland, Ravi S. Chari, F-Prime Capital Partners, Abir Sen, Bijan Salehizadeh, Carl Bradford Byers 🚑, Jonathan Bush, Kal Vepuri, Bessemer Venture Partners, F-Prime Capital, Silicon Badia, Zimmerman Ventures.
Lumere has raised $15.0M across 3 funding rounds. Most recently, it raised $10.0M Other Equity in June 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 14, 2016 | $10.0M Other Equity | Jesse Bland | Ravi S. Chari |
| Mar 21, 2014 | $4.0M Series A | ||
| Aug 1, 2012 | $1.0M Seed | F-Prime Capital Partners, Abir Sen, Bijan Salehizadeh, Carl Bradford Byers 🚑, Jonathan Bush, Kal Vepuri, Bessemer Venture Partners, F-Prime Capital, Silicon Badia, Zimmerman Ventures |